Medios AG, a leading European Specialty Pharma provider, has announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, who brings nearly two decades of experience in capital markets communications, will oversee the company's interactions with investors, analysts, media, and the public, succeeding Claudia Nickolaus.
Neuffer's career includes a decade-long tenure at SDAX-listed Wacker Neuson SE, where she served as Head of Investor Relations & Corporate Communications from 2007 to 2018, guiding the company through its IPO and establishing it as a consistently attractive investment. She also led the Strategy and Sustainability departments there. Subsequently, she held the position of Vice President Investor Relations & Corporate Communications and Marketing at Exyte Group (formerly M+W Group), where she managed an international team of 20 and was responsible for preparing an IPO targeting a market capitalization of more than EUR 2 billion. Since 2020, she has been advising publicly listed companies as an independent consultant on investor relations, IPO preparation, and crisis and restructuring communications.
Thomas Meier, CEO of Medios AG, expressed confidence in the appointment: “With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media.” He also extended gratitude to Claudia Nickolaus for her years of dedication in shaping Medios' capital markets communications.
The leadership change comes as Medios prepares for several key events in the 2026 financial year, including the Half-Year Financial Report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21-23, the Medios Capital Markets Day on September 28/29, and the Quarterly Statement on November 10.
Medios AG is recognized as Germany's first listed specialty pharmaceutical company, with shares traded on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. The company operates across Germany, the Netherlands, Belgium, and Spain, focusing on pioneering individualized medicine to enhance the availability of innovative therapies for patients, in collaboration with pharmacies, specialist practices, and pharmaceutical companies.
For more information about Medios and its initiatives, visit www.medios.group and explore details on individualized medicine at app.medios.group/en/individualizedmedicine.
